and one anti-CD38 monoclonal antibody. NICE recommended Elrexfio and Tecvayli with what it calls 'optimised' guidance, which means that they can be used with modifications to the MHRA-approved ...

“This is a natural place for a platform proof-of-concept, because monoclonal antibodies against CD38 have been approved for the indication, and anti-CD3 antibodies have been shown to redirect ...

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...

of intravenous HexaBody-CD38 versus subcutaneous daratumumab in patients with anti-CD38 antibody- naïve relapsed or refractory multiple myeloma. Preliminary data submitted by Genmab to J&J ...

CD38 monoclonal antibodies, bispecific antibodies, and CAR T-cell therapies are pivotal in multiple myeloma management, offering deep responses and manageable toxicities. Comprehensive molecular ...